Q3 Results:
Abbott India Q3 Results: Total income for Q3 FY25 rose by 12.9% to ₹1,686.03 crore, from ₹1,492.75 crore in the same period last year. Net profit increased by 16% to ₹360.78 crore, compared to ₹310.98 crore in Q3 FY24.
Abbott India Limited provides diagnostics solutions, medical devices, nutritional products, and pharmaceuticals. Founded in 1910, Abbott India has many years of experience in healthcare. This makes it a longstanding player in the industry. Its headquarters are located in Mumbai, Maharashtra. Main products include diagnostics solutions, medical devices, and pharmaceuticals. Abbott India operates in the healthcare sector. It is contributing significantly to the industry through its diverse product offerings and commitment to innovation and quality. The company also engages in corporate social responsibility initiatives. It supports community development programs and environmental sustainability projects. +
No data available
No data available
No data available
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 6,097.18 | 5,502.88 | 4,996.48 | 4,390.92 | 4,207.53 |
Total Expenses | 4,479.43 | 4,229.06 | 3,916.75 | 3,464.97 | 3,404.83 |
Profit Before Tax | 1,617.75 | 1,273.82 | 1,079.73 | 925.95 | 802.70 |
Profit After Tax | 1,201.22 | 949.41 | 798.70 | 690.69 | 592.93 |
Operating Profit After Depreciation | 1,630.20 | 1,289.81 | 1,098.83 | 944.23 | 811.23 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 224.94 | 236.91 | 271 | 250.78 | 269.83 |
Total Non Current Assets | 1,947.65 | 1,530.40 | 371.08 | 353.04 | 342.20 |
Total Current Assets | 3,245.84 | 3,025.11 | 3,853.04 | 3,487.41 | 3,204.65 |
Total Assets | 5,193.49 | 4,555.51 | 4,224.12 | 3,840.45 | 3,546.85 |
Total Shareholder's Fund | 3,698.89 | 3,188.54 | 2,819.79 | 2,602.16 | 2,431.70 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash From Operating Activities | 1,212.81 | 893.39 | 947.66 | 726.74 | 626.13 |
Net Cash Used In Investing Activities | -416.03 | -147.71 | -395.84 | -71.82 | -401.21 |
Net Cash Used In Financing Activities | -744.71 | -638.72 | -637.38 | -581.79 | -216.79 |
No data available
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 1,614.28 | 1,632.67 | 1,557.61 | 1,438.63 | 1,437.14 |
Total Expenses | 1,178.19 | 1,193.71 | 1,166.60 | 1,109.10 | 1,049.45 |
Profit Before Tax | 487.59 | 479.43 | 437.22 | 389.68 | 422.16 |
Profit After Tax | 360.78 | 358.61 | 328.01 | 287.06 | 310.98 |
Operating Profit after Depreciation | 507.84 | 499.44 | 458.34 | 410.68 | 443.30 |
₹410.0/Share
Company | Price | Market Cap (in Cr) |
---|---|---|
Sun Pharmaceutical Industries Ltd | ₹1,751.05 | ₹4,20,135.55 |
Divis Laboratories Ltd | ₹5,638.35 | ₹1,49,680.48 |
Cipla Ltd | ₹1,515.45 | ₹1,22,390.34 |
Torrent Pharmaceuticals Ltd | ₹3,254.85 | ₹1,10,153.97 |
Mankind Pharma Ltd | ₹2,582.65 | ₹1,06,554.59 |
Fund Name | AUM |
---|---|
SBI Large & Midcap Fund | 2.87% |
AXIS Midcap Fund | 1.80% |
Canara Robeco Emerging Equities | 1.94% |
SBI Magnum Global Fund | 5.14% |
Nippon India Pharma Fund | 3.46% |
16 Apr 2025, 02:57 pm
16 Apr 2025, 09:38 am
20 Feb 2025, 09:28 am
Abbott India Ltd is quoting at Rs 27903.95, down 1.6% on the day as on 13:19 IST on the NSE. The stock tumbled 4.39% in last one year as compared to a 4.2% rally in NIFTY and a 11.87% spurt in the Nifty Pharma index.
14 Feb 2025, 01:35 pm
Abbott India Ltd is quoting at Rs 29440, up 1.23% on the day as on 12:44 IST on the NSE. The stock is up 4.18% in last one year as compared to a 8.59% jump in NIFTY and a 19.15% jump in the Nifty Pharma.
07 Feb 2025, 01:00 pm
*By clicking, I agree to the T&C and Whatsapp updates.